Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.53 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.53 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343810 | 0.81 | GFER (0.52) | SMN1; SMN2KCNJ6KCNJ5KCNJ3KDM4C | |
| SCHEMBL5012000 | 0.80 | HTT (0.56) | SMN1; SMN2KDM4CMAPTMEN1KMT2A | |
| SCHEMBL6344420 | 0.78 | GFER (0.49) | KCNJ6KCNJ5KCNJ3KDM4CMAPT | |
| SCHEMBL6343392 | 0.76 | KMT2A (0.61) | SMN1; SMN2MAPTMEN1KMT2ACLCN2 | |
| Trifluoroacetic Acid SCHEMBL27617932 | 0.75 | MAPK1 (0.56) | SMN1; SMN2KDM4CMAPTMEN1KMT2A | |
| SCHEMBL5465583 | 0.75 | GAA (0.62) | MAPTMEN1KMT2ACLCN2GFER | |
| SCHEMBL691573 | 0.74 | MAPK1 (0.50) | SMN1; SMN2KDM4CMEN1KMT2ACLCN2 | |
| SCHEMBL5178107 | 0.70 | GRN (0.67) | SMN1; SMN2KCNJ6KCNJ5KCNJ3MAPT | |
| SCHEMBL848085 | 0.69 | AKR1C3 (0.60) | SMN1; SMN2MAPTCLCN2GFER | |
| SCHEMBL22000813 | 0.69 | HDAC3 (0.55) | SMN1; SMN2MAPTMEN1KMT2AP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | SMN1; SMN2 4113/4885KCNJ6 1526/4885KCNJ5 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.